MetaVia Hit With Nasdaq Deficiency Notice After Equity Falls Below $2.5M
MTVA sits 27% above its 52-week low of $0.966.
Summary
MetaVia received a Nasdaq notice that its stockholders' equity is below the $2.5 million continued-listing minimum, with no alternative standard met. It has until January 4, 2027 to submit a compliance plan, and the likely fix is another dilutive raise.
Key Events · Legal and Risk Events · MTVA
-
Nasdaq Minimum Equity Deficiency
Nasdaq notified MetaVia on November 17, 2026 that stockholders' equity reported in the September 30, 2026 10-Q fell below the $2.5 million required by Listing Rule 5550(b)(1), and the company does not meet the alternative compliance standards.
-
Compliance Plan Due January 4, 2027
The company has 45 calendar days from the notice to submit a plan to regain compliance; if Nasdaq accepts it, the company may get up to 180 additional calendar days to evidence compliance.
-
Trading Continues For Now
The notice has no immediate impact on listing — MTVA keeps trading on the Nasdaq Capital Market under its current symbol.
-
Balance Sheet Pressure Behind the Notice
The equity shortfall follows a previously disclosed going-concern warning and $8.8M of cash that management says funds operations into 1Q 2027, making another equity raise the most likely route to compliance.
Analysis · MTVA · Life Sciences
Nasdaq has told MetaVia that its stockholders' equity has dropped below the $2.5 million minimum for continued listing, and the company does not qualify under any alternative standard. This lands on top of a going-concern warning already in the Q3 10-Q and only $8.8M of cash that management says lasts into 1Q 2027 — so the company now has to fix its balance sheet on a regulatory clock, most likely by issuing more stock. The notice itself does not halt trading, but a delisting would crush liquidity for a micro-cap biotech. The next hard date is January 4, 2027, when the compliance plan is due; Nasdaq can then extend the process by up to 180 days.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 52.4% of the 208 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.91%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MTVA was trading at $1.23 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.4M. The 52-week trading range was $0.97 to $13.42. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.